Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23–24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collection of frequent or continuous, objective, and multidimensional data during daily activities may capture subtle changes in cognition and functional capacity long before the onset of dementia. The potential to exploit these technologies to improve clinical trials as both recruitment and retention tools as well as for potential end points was discussed. The implications for the collection and use of large amounts of data, lessons learned from other related disease areas, ethical concerns raised by these new technologies, and regulatory issues were also covered in the meeting. Finally, the challenges and opportunities of these new technologies for future use were discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Video game training enhances cognitive control in older adults
Anguera, J. A., Boccanfuso, J., Rintoul, J. L., Al-Hashimi, O., Faraji, F., Janowich, J., Kong, E., Larraburo, Y., Rolle, C., Johnston, E., et al. (2013) · Nature · doi:10.1038/nature12486 · Cited by 1,666
Connected Speech in Neurodegenerative Language Disorders: A Review
Boschi, V., Catricalà, E., Consonni, M., Chesi, C., Moro, A., & Cappa, S. F. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.00269 · Cited by 362
Obstacles and opportunities in Alzheimer’s clinical trial recruitment
Watson, J. L., Ryan, L., Silverberg, N., Cahan, V., & Bernard, M. A. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1314 · Cited by 204 · cited 1×
“Improving subject recruitment, retention, and compliance is essential to the goal of developing effective treatments for AD [19,20].”
BackgroundUnobtrusive assessment of activity patterns associated with mild cognitive impairment
Hayes, T. L., Abendroth, F., Adami, A., Pavel, M., Zitzelberger, T. A., & Kaye, J. A. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.07.004 · Cited by 187 · cited 1×
“High-frequency, in-home monitoring data have also been shown to distinguish individuals with mild cognitive impairment from those with normal cognition [5,6], suggesting that such data could reduce sample sizes needed for clinical trials and thus reduce exposure of participants to potentially harmful drugs [7].”
BackgroundThe use of smartphones for health research
Dorsey, E. R., “Yvonne” Chan, Y.-F., McConnell, M. V., Shaw, S. Y., Trister, A. D., & Friend, S. H. (2017) · Academic Medicine · doi:10.1097/acm.0000000000001205 · Cited by 154
Novel Methods and Technologies for 21st-Century Clinical Trials: A Review
Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118 · cited 1×
“For example, high variability in scores of existing cognitive tests at baseline and over the course of a trial has produced false signals in phase 2 studies that contributed to costly failures in phase 3 [1].”
BackgroundUse of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials
Dodge, H. H., Zhu, J., Mattek, N. C., Austin, D., Kornfeld, J., & Kaye, J. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138095 · Cited by 99 · cited 1×
“High-frequency, in-home monitoring data have also been shown to distinguish individuals with mild cognitive impairment from those with normal cognition [5,6], suggesting that such data could reduce sample sizes needed for clinical trials and thus reduce exposure of participants to potentially harmful drugs [7].”
Background
Research works printed but not linked: 30
- 10.1177/0733464815570667 · DOI
- 10.1056/NEJMoa1510774 · DOI · Paper page
- 10.3233/JAD-130272 · DOI · Paper page
- 10.1212/WNL.0b013e318259e1de · DOI · Paper page
- 10.1093/geronb/gbq095 · DOI · Paper page
- Lyons B.E., 2015, Pervasive computing technologies to continuously assess Alzheimer's disease progression and intervention efficacy, Front Aging Neurosci, 7, 102
- 10.1016/j.dadm.2015.09.006 · DOI · Paper page
- Muller S., 2017, Increased diagnostic accuracy of digital vs. conventional clock drawing test for discrimination of patients in the early course of Alzheimer's disease from cognitively healthy individuals, Front Aging Neurosci, 9, 101, 10.3389/fnagi.2017.00101 · DOI
- Forbes K.E., 2002, Distinct patterns of spontaneous speech deterioration: an early predictor of Alzheimer's disease, Brain Cogn, 48, 356, 10.1006/brcg.2001.1377 · DOI
- 10.1016/j.bandl.2016.07.008 · DOI · Paper page
- C.Leurent E.Pickering J.Goodman S.Duvvuri P.He E.Martucci et al.A Randomized Double‐Blind Placeo Controlled Trial to Study Difference in Cognitive Learning Associated with Repeated Self‐administration of Remote Computer Tablet‐based Application Assessing Dual Task Performance Based on Amyloid Status in Healthy Elderly Volunteers Clinical Trials in Alzheimer's Disease 9th conference; San Diego CA USA: J Prev Alz Dis2016;281
- 10.1016/j.dadm.2015.10.005 · DOI
- 10.1097/WAD.0000000000000016 · DOI · Paper page
- Rudick R.A., 2014, The Multiple Sclerosis Performance Test (MSPT): an iPad‐based disability assessment tool, J Vis Exp, 88, e51318
- 10.1177/1352458516688955 · DOI
- 10.1093/oxfordjournals.schbul.a006873 · DOI · Paper page
- Keefe R.S., 2016, Report on ISCTM consensus meeting on clinical assessment of response to treatment of cognitive impairment in Schizophrenia, Schizophr Bull, 42, 19
- 10.1016/j.schres.2016.03.038 · DOI
- 10.1147/JRD.2017.2768739 · DOI
- Hunter J., 2016, Privacy Breach in B.C. Health Ministry Led to Freeze on Medical Research Data
- Beach S., 2009, Disability, age, and informationial privacy attitudes in quality of life technology applications: Results from a national web survey, ACM Trans Access Comput, 2, 10.1145/1525840.1525846 · DOI · Paper page
- 10.1016/j.dadm.2015.03.004 · DOI
- Albrecht U.V., 2013, App‐synopsis ‐ standard reporting for medical apps, Stud Health Technol Inform, 192, 1154
- 10.1002/pra2.2015.145052010043 · DOI
- 10.2196/mhealth.6521 · DOI · Paper page
- 10.1300/J151v01n01_03 · DOI
- 10.1016/j.jagp.2012.11.009 · DOI
- 10.1016/j.trci.2016.09.001 · DOI
- 10.1177/1049732309359171 · DOI · Paper page
- Isaac M.T., 2017, Diagnostic biomarkers for Alzheimer's disease: A regulatory view, Lancet Neurol, 16, 580, 10.1016/S1474-4422(17)30223-5 · DOI
Cited by
Precision medicine, AI, and the future of personalized health care
Johnson, K. B., Wei, W., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., & Snowdon, J. L. (2021) · Clinical and Translational Science · doi:10.1111/cts.12884 · Cited by 1,854
“94 In the field of cancer care, evolving technology using wearable devices continuously analyzes circulating tumor cells to screen for relapsed disease.”
BackgroundIntroduction to artificial intelligence in medicine
Mintz, Y., & Brodie, R. (2019) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645706.2019.1575882 · Cited by 784
Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare
Cirillo, D., Catuara-Solarz, S., Morey, C., Guney, E., Subirats, L., Mellino, S., Gigante, A., Valencia, A., Rementeria, M. J., Chadha, A. S., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0288-5 · Cited by 553
“…that indicates the potential for developing a disease or medical condition in an individual who does not currently have clinically apparent disease or medical condition. a Detect cognitive changes in healthy subjects at risk of developing Alzheimer ’ s disease using a video game platform 139 .”
MethodDeveloping and adopting safe and effective digital biomarkers to improve patient outcomes
Coravos, A., Khozin, S., & Mandl, K. D. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0090-4 · Cited by 361
Inan, O. T., Tenaerts, P., Prindiville, S. A., Reynolds, H. R., Dizon, D. S., Cooper-Arnold, K., Turakhia, M., Pletcher, M. J., Preston, K. L., Krumholz, H. M., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0302-y · Cited by 329
“Enrollment rates may be severely curtailed if enrolling a representative population takes priority 16,17 .”
Background
Metadata
- Authors
- Gold, M., Amatniek, J., Carrillo, M. C., Cedarbaum, J. M., Hendrix, J. A., Miller, B. B., Robillard, J. M., Rice, J. J., Soares, H., Tome, M. B., Tarnanas, I., Vargas, G., Bain, L. J., & Czaja, S. J.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 234-242
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2803176146
- Cited by
- 143
- References
- 8
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. https://app.cochat.ai/papers/10.1016/j.trci.2018.04.003
- The paper
- Gold, M., Amatniek, J., Carrillo, M. C., Cedarbaum, J. M., Hendrix, J. A., Miller, B. B., Robillard, J. M., Rice, J. J., Soares, H., Tome, M. B., Tarnanas, I., Vargas, G., Bain, L. J., & Czaja, S. J. (2018). Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1016/j.trci.2018.04.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.